Neoadjuvant Erlotinib for Operable Stage II or IIIA NSCLC With EGFR Mutations

NCT01470716 · clinicaltrials.gov ↗

PHASE2

Phase

UNKNOWN

Status

26

Enrollment

OTHER_GOV

Sponsor class

Conditions

NSCLC Stage II
NSCLC, Stage IIIA

Interventions

DRUG: Erlotinib

Sponsor

National Cancer Center, Korea

Collaborators

[object Object]